AU2014209107B2 - Metalloenzyme inhibitor compounds - Google Patents

Metalloenzyme inhibitor compounds Download PDF

Info

Publication number
AU2014209107B2
AU2014209107B2 AU2014209107A AU2014209107A AU2014209107B2 AU 2014209107 B2 AU2014209107 B2 AU 2014209107B2 AU 2014209107 A AU2014209107 A AU 2014209107A AU 2014209107 A AU2014209107 A AU 2014209107A AU 2014209107 B2 AU2014209107 B2 AU 2014209107B2
Authority
AU
Australia
Prior art keywords
phenyl
naphthyridin
hydrazinecarbonyl
ethynyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
AU2014209107A
Other languages
English (en)
Other versions
AU2014209107A1 (en
Inventor
William J. Hoekstra
Stephen W. Rafferty
Christopher M. Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mycovia Pharmaceuticals Inc
Original Assignee
Viamet Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viamet Pharmaceuticals Inc filed Critical Viamet Pharmaceuticals Inc
Publication of AU2014209107A1 publication Critical patent/AU2014209107A1/en
Assigned to Viamet Pharmaceuticals (NC), Inc. reassignment Viamet Pharmaceuticals (NC), Inc. Amend patent request/document other than specification (104) Assignors: VIAMET PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2014209107B2 publication Critical patent/AU2014209107B2/en
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2014209107A 2013-01-28 2014-01-27 Metalloenzyme inhibitor compounds Revoked AU2014209107B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361757594P 2013-01-28 2013-01-28
US61/757,594 2013-01-28
PCT/US2014/013204 WO2014117090A1 (en) 2013-01-28 2014-01-27 Metalloenzyme inhibitor compounds

Publications (2)

Publication Number Publication Date
AU2014209107A1 AU2014209107A1 (en) 2015-08-06
AU2014209107B2 true AU2014209107B2 (en) 2018-04-12

Family

ID=51228112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014209107A Revoked AU2014209107B2 (en) 2013-01-28 2014-01-27 Metalloenzyme inhibitor compounds

Country Status (6)

Country Link
US (1) US9663488B2 (enExample)
EP (1) EP2948450A4 (enExample)
JP (1) JP2016508487A (enExample)
AU (1) AU2014209107B2 (enExample)
CA (1) CA2898615A1 (enExample)
WO (1) WO2014117090A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10221160B2 (en) 2012-01-20 2019-03-05 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
ES2800905T3 (es) 2014-03-19 2021-01-05 Mycovia Pharmaceuticals Inc Procedimiento para compuesto antifúngico
EP3119755B1 (en) 2014-03-19 2019-03-06 Viamet Pharmaceuticals (NC), Inc. Antifungal compound process
ES2815373T3 (es) 2014-03-19 2021-03-29 Mycovia Pharmaceuticals Inc Procedimiento de compuesto antifúngico
CN106103424A (zh) 2014-03-19 2016-11-09 维亚梅特制药公司 2‑(2,4‑二氟苯基)‑1,1‑二氟‑1‑(5‑经取代的吡啶‑2‑基)‑3‑(1h‑四唑‑1‑基)丙烷‑2‑醇和其制备方法
US10017494B2 (en) 2014-03-19 2018-07-10 Mycovia Pharmaceuticals, Inc. Antifungal compound process
US10399943B2 (en) 2014-03-19 2019-09-03 Mycovia Pharmaceuticals, Inc. Antifungal compound process
MX2016012060A (es) 2014-03-19 2017-01-19 Viamet Pharmaceuticals Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
US10196375B2 (en) 2014-03-19 2019-02-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CA2942932A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
JP6618530B2 (ja) 2014-09-09 2019-12-11 バイエル ファーマ アクチエンゲゼルシャフト 置換ｎ，２−ジアリールキノリン−４−カルボキサミドおよび抗炎症剤としてのその使用
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
WO2016146602A1 (de) * 2015-03-18 2016-09-22 Bayer Pharma Aktiengesellschaft Substituierte n-bicyclo-2-arylchinolin-4-carboxamide und ihre verwendung
EA037521B1 (ru) 2015-09-18 2021-04-07 ВиПиЭс-3, ИНК. Противогрибковые соединения и способы их получения
CN105272896A (zh) * 2015-10-19 2016-01-27 山东国润生物医药有限公司 (（2s）-2-氮丙啶基)二苯基甲醇的制备方法
US10611747B2 (en) 2015-11-09 2020-04-07 Forge Therapeutics, Inc. Pyrone based compounds for treating bacterial infections
US10414735B2 (en) 2015-11-09 2019-09-17 Forge Therapeutics, Inc. Substituted hydroxypyrimidinones for treating bacterial infections
WO2017153234A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
WO2017153231A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung
JP2019142776A (ja) * 2016-06-24 2019-08-29 石原産業株式会社 Ｎ−（４−ピリジル）ベンズアミド化合物又はその塩を有効成分として含有する有害生物防除剤
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
PH12019502314A1 (en) 2017-04-10 2020-10-26 Bayer Ag Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
WO2018204176A1 (en) 2017-05-01 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
US11021471B2 (en) 2017-05-10 2021-06-01 Forge Therapeutics, Inc. Antibacterial compounds
EP4438042A3 (en) * 2018-06-22 2024-12-04 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase
AU2019345150A1 (en) 2018-09-20 2021-05-13 Blacksmith Medicines, Inc. Antibacterial compounds
CN109456205B (zh) * 2018-12-17 2021-09-21 石河子大学 以取代喹啉或异喹啉酰肼吡啶-n-氧化物为配体的水相体系中的n-芳基化方法
EP3725788A1 (en) * 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
WO2021195260A1 (en) 2020-03-25 2021-09-30 Forge Therapeutics, Inc. Lpxc inhibitor and methods of making
JP2024536864A (ja) 2021-09-28 2024-10-08 ブラックスミス メディシンズ，インク． Ｌｐｘｃ阻害剤およびその使用
WO2023219456A1 (ko) * 2022-05-12 2023-11-16 숙명여자대학교 산학협력단 퀴놀린 계열 히스톤디아세틸화 효소 저해활성물질, 이의 제조방법 및 이를 유효성분으로 포함하는 약학적 조성물
WO2023231964A1 (zh) * 2022-05-30 2023-12-07 赛诺哈勃药业（成都）有限公司 四氢萘啶衍生物在制备防治粘连相关疾病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008105515A1 (ja) * 2007-02-28 2008-09-04 Taisho Pharmaceutical Co., Ltd. 新規なヒドロキサム酸誘導体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA845594B (en) * 1983-07-22 1986-03-26 Du Pont Phenylquinolinecarboxylic acids and derivatives as antitumor agents
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids
JPH083163A (ja) * 1994-06-22 1996-01-09 Kyowa Hakko Kogyo Co Ltd 縮合ピリジン誘導体
AU4007900A (en) * 1999-03-11 2000-10-16 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
WO2001024785A2 (en) * 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
US6828329B2 (en) * 2000-06-26 2004-12-07 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
JP2004506038A (ja) * 2000-08-16 2004-02-26 ニューロゲン　コーポレイション ２，４−置換ピリジン誘導体
US20040110802A1 (en) * 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
CA2540342A1 (en) * 2003-10-31 2005-05-12 Neurogen Corporation 4-amino (aza) quinoline derivatives as capsaicin receptor agonists
MXPA06006532A (es) * 2003-12-09 2006-08-23 Vertex Pharma Derivados de naftiridina y su uso como moduladores de receptores muscarinicos.
WO2006034512A2 (en) * 2004-09-23 2006-03-30 Bayer Pharmaceuticals Corporation Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
JP2009528289A (ja) * 2006-02-27 2009-08-06 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
CN101084895B (zh) * 2007-06-22 2011-11-23 复旦大学 一种葡萄球菌色氨酰-tRNA合成酶抑制剂
JP2011517313A (ja) * 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
WO2010024356A1 (ja) * 2008-08-27 2010-03-04 大正製薬株式会社 ナフチリジン－ｎ－オキシドを有する新規ヒドロキサム酸誘導体
WO2010094009A2 (en) * 2009-02-13 2010-08-19 Children's Hospital Medical Center Methods and compositions for the treatment of ras associated disorders
CA2785898C (en) * 2009-12-31 2018-07-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
RU2450025C2 (ru) * 2010-07-16 2012-05-10 Учреждение Российской академии наук Институт высокомолекулярных соединений РАН МЕТАЛЛ-ПОЛИМЕРНЫЙ КОМПЛЕКС ЕВРОПИЯ (Eu3+) И (СО)ПОЛИ-(МЕТИЛМЕТАКРИЛАТ)-(1-МЕТАКРИЛОИЛ-2-(2-ПИРИДИЛ)-4-КАРБОКСИХИНОЛИЛ)ГИДРАЗИНА
BR112013014484A2 (pt) * 2010-12-13 2016-07-19 Viamet Pharmaceuticals Inc compostos inibidores de metaloenzimas
CN103492368A (zh) * 2011-04-08 2014-01-01 辉瑞大药厂 用作抗菌剂的咪唑、吡唑和噻唑衍生物
EP2721023B1 (en) * 2011-06-19 2018-08-08 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
EP2847168A1 (en) * 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008105515A1 (ja) * 2007-02-28 2008-09-04 Taisho Pharmaceutical Co., Ltd. 新規なヒドロキサム酸誘導体

Also Published As

Publication number Publication date
CA2898615A1 (en) 2014-07-31
EP2948450A1 (en) 2015-12-02
AU2014209107A1 (en) 2015-08-06
US9663488B2 (en) 2017-05-30
EP2948450A4 (en) 2016-11-09
JP2016508487A (ja) 2016-03-22
US20150353546A1 (en) 2015-12-10
WO2014117090A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
AU2014209107B2 (en) Metalloenzyme inhibitor compounds
US12227524B2 (en) Anti-infective compounds
US10464922B2 (en) Metalloenzyme inhibitor compounds
US9765054B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US12084420B2 (en) Indoline compounds for inhibiting KIF18A
KR102690885B1 (ko) 금속효소 억제제 화합물
US9718782B2 (en) TrkA kinase inhibitors, compositions and methods thereof
JP7759877B2 (ja) 治療用化合物
US20230382889A1 (en) Compounds for inhibiting kif18a
BRPI0620655A2 (pt) inibidores de pdf
WO2012072033A1 (zh) 取代的2，3-二氮杂萘酮化合物及其用途
EP3096754A1 (en) Metallo-beta-lactamase inhibitors
JP2017039765A (ja) タンパク質キナーゼ阻害薬
AU2011326487A1 (en) Metalloenzyme inhibitor compounds
US9855267B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP2976341A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
JP2023513373A (ja) Ｐ２ｘ３修飾薬
US10106535B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
KR20140117651A (ko) 이소퀴놀린 및 나프티리딘 유도체
WO2023131690A1 (en) Substituted heterocycles as hset inhibitors
AU2004210774A1 (en) Substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands
NZ613087B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: VIAMET PHARMACEUTICALS (NC), INC.

Free format text: FORMER NAME(S): VIAMET PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)
ROP Revocation of patent

Effective date: 20190212